Amgen lays off about 300 workers, citing 'industry headwinds'
Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers all the big issues faced by biopharma. This transcript has been edited for brevity and clarity. I think 2022 had to be one of the worst years ever…
#johncarroll #catalent #alessandromaselli #federalreserve